Auxilium Biotechnologies

HardwareSan Diego, California, USAFounded 2019· One of 1805 Hardware companies tracked by AMPulse

Auxilium Biotechnologies develops 3D bioprinting technology for producing implantable medical devices, with a focus on peripheral nerve repair.

CEO / Founder: Jacob Koffler
Team Size: 11-50
Stage: Active
Total Funding: $7.19M
Key Investors: Sequoia China (红杉中国), CF Ventures, Innovation Partnerships, University of California

Technology & Products

Key Products

AMP-1 bioprinting platform, bioprinting solutions and implantable medical devices for traumatic nervous system injuries, space-based bioprinted kidney/liver/cartilage tissues

Technological Advantage

Ability to fabricate complex biomedical structures in space, which is not possible with conventional Earth-based 3D bioprinting methods.

Differentiation

Value Proposition

Delivers precise and uniform medical implants through microgravity-based 3D bioprinting, overcoming the manufacturing limitations of Earth-based processes.

How They Differentiate

Focuses on space-based biomanufacturing to achieve microgravity-enabled structural advantages, setting it apart from traditional bioprinting companies.

Market & Competition

Target Customers

Medical institutions and patients requiring nerve repair treatments

Industry Verticals

Biomedical, Neurological

Competitors

Organovo Holdings; Aspect Biosystems; Regeneron Pharmaceuticals

Growth & Milestones

Growth Metrics

Successful deployment on the ISS and development of novel medical devices

Major Milestones

Successful launch and operation of the AMP-1 bioprinter on the ISS, Development of the Gen 1.0 NeuroSpan Bridge, First successful bioprinting of kidney and liver tissues in space (July 2026), First mission to manufacture three distinct tissue types during a single spaceflight (July 2026), Production of 28 nerve repair implants during AXLM-3 mission (June 2026)

Notable Customers

Starlab Space; Wake Forest Institute for Regenerative Medicine; clinical trial participants (multicenter study)

https://www.auxiliumbio.com

Recent coverage of Auxilium Biotechnologies

Why this company matters

AMPulse analysis, not a company disclosure

Auxilium Biotechnologies occupies a unique position at the intersection of space manufacturing and regenerative medicine. While most bioprinting companies focus on Earth-based extrusion, Auxilium leverages the microgravity environment of the International Space Station to fabricate implantable medical devices with structural precision and material uniformity that are difficult to achieve under gravity. This approach targets a specific clinical gap: peripheral nerve repair, where current grafts and conduits often fail to guide regeneration effectively.

The company's core technology is the AMP-1 bioprinting platform, which operates on the ISS using a material extrusion (MEX) process adapted for microgravity. Its lead product candidate, the Gen 1.0 NeuroSpan Bridge, is designed to treat traumatic nervous system injuries. By printing in space, Auxilium aims to produce constructs with more consistent fiber alignment and cell distribution, potentially improving functional recovery outcomes compared to conventional nerve grafts or Earth-printed alternatives.

Auxilium serves medical institutions and patients requiring nerve repair treatments. It has conducted a multicenter clinical study and partnered with Starlab Space for continued orbital manufacturing. Key collaborations include Space Tango for ISS integration, Invetech for engineering support, and NASA through the InSpa program. The company has raised $7.19M from investors including Sequoia and CF Ventures, and successfully deployed the AMP-1 printer on the ISS.

The strategic moat lies in first-mover access to microgravity biomanufacturing infrastructure and the IP around space-optimized bioprinting processes. However, the model carries execution risk: reliance on ISS access, high launch costs, and a narrow initial indication. Competitors like Organovo and Aspect Biosystems are advancing Earth-based bioprinting for broader tissue applications, and Regeneron's expertise in biologics could converge on nerve repair. Auxilium's long-term differentiation depends on whether microgravity yields clinically superior implants that justify the added complexity of space manufacturing.